Comparative Pharmacology
Head-to-head clinical analysis: ALYACEN 1 35 versus JENCYCLA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYACEN 1 35 versus JENCYCLA.
ALYACEN 1/35 vs JENCYCLA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
JENCYCLA (sodium phenylbutyrate and ursodoxicoltaurine) is a fixed-dose combination. Sodium phenylbutyrate is a nitrogen-binding agent that conjugates with glutamine to form phenylacetylglutamine, which is excreted renally, reducing ammonia levels. Ursodoxicoltaurine is a hydrophilic bile acid that replaces toxic bile salts, reduces hepatocyte apoptosis, and improves bile flow.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
1-2 mg/kg IV once daily every 3-4 weeks; maximum dose 100 mg.
None Documented
None Documented
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
8-12 hours; prolonged to 24 hours in severe hepatic impairment
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
Renal: 35-45% unchanged; biliary/fecal: 50-60% as metabolites
Category C
Category C
Oral Contraceptive
Oral Contraceptive